Introduction
Executive Summary
Endometriosis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Linzagolix: ObsEva
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Quinagolide: Ferring Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
• Comparative Analysis
BOL-DP-o-08: Breath of Life International Pharma Ltd
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Endometriosis Key Companies
Endometriosis Key Products
Endometriosis- Unmet Needs
Endometriosis- Market Drivers and Barriers
Endometriosis- Future Perspectives and Conclusion
Endometriosis Analyst Views
Endometriosis Key Companies
Appendix

List of Tables
Table 1 Total Products for Endometriosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Endometriosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• ObsEva SA
• Myovant Sciences
• Dexa Medica Group
• Ferring Pharmaceuticals
• Merck Sharp & Dohme Corp.
• Bayer
• Breath of Life International Pharma Ltd
• Jiangsu HengRui Medicine Co., Ltd.
• Forendo Pharma
• Mitsubishi Tanabe Pharma Corporation
• Chugai Pharmaceutical
• Nippon Shinyaku
• ValiRx
• Temple therapeutics
• Celmatix
• Camurus
• Enteris BioPharma
• Preglem Reproductive Medicines
• Viramal